| Literature DB >> 30607032 |
Noemie Jourde-Chiche1,2, Fadi Fakhouri3, Laetitia Dou4, Jeremy Bellien5, Stéphane Burtey6,4, Marie Frimat7,8, Pierre-André Jarrot4,9, Gilles Kaplanski4,9, Moglie Le Quintrec10,11, Vincent Pernin10,11, Claire Rigothier12,13, Marion Sallée6,4, Veronique Fremeaux-Bacchi14,15, Dominique Guerrot16, Lubka T Roumenina17,18,19.
Abstract
The kidney harbours different types of endothelia, each with specific structural and functional characteristics. The glomerular endothelium, which is highly fenestrated and covered by a rich glycocalyx, participates in the sieving properties of the glomerular filtration barrier and in the maintenance of podocyte structure. The microvascular endothelium in peritubular capillaries, which is also fenestrated, transports reabsorbed components and participates in epithelial cell function. The endothelium of large and small vessels supports the renal vasculature. These renal endothelia are protected by regulators of thrombosis, inflammation and complement, but endothelial injury (for example, induced by toxins, antibodies, immune cells or inflammatory cytokines) or defects in factors that provide endothelial protection (for example, regulators of complement or angiogenesis) can lead to acute or chronic renal injury. Moreover, renal endothelial cells can transition towards a mesenchymal phenotype, favouring renal fibrosis and the development of chronic kidney disease. Thus, the renal endothelium is both a target and a driver of kidney and systemic cardiovascular complications. Emerging therapeutic strategies that target the renal endothelium may lead to improved outcomes for both rare and common renal diseases.Entities:
Mesh:
Year: 2019 PMID: 30607032 DOI: 10.1038/s41581-018-0098-z
Source DB: PubMed Journal: Nat Rev Nephrol ISSN: 1759-5061 Impact factor: 28.314